Linezolid

Drug Profile

Linezolid

Alternative Names: PNU 100766; U 100766; Zyvox; Zyvoxam; Zyvoxid

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Acetamides; Antibacterials; Oxazolidinones; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Methicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant enterococcal infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections; Community-acquired pneumonia; Diabetic foot ulcer; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Nosocomial infections; Nosocomial pneumonia; Skin and soft tissue infections; Vancomycin-resistant enterococcal infections

Most Recent Events

  • 25 Jun 2015 Pfizer terminates a phase III trial in Optic nerve disorders in USA, Italy and Sweden (NCT00359632)
  • 01 Jan 2014 Seoul National University Hospital initiates a phase II trial in Tuberculosis (pulmonary) in South Korea (NCT01994460)
  • 22 Oct 2010 Efficacy data from a phase IV trial (ZEPHyR) in Nosocomial pneumonia due to MRSA released by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top